Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
Recently, two new oral P2Y12 antagonists have been approved for clinical use: prasugrel, a
third generation thienopyridine, and ticagrelor, a first in class
cyclopentyltriazolopyrimidine (CPTP). These agents have been shown to be associated with more
potent platelet inhibitory effects compared with clopidogrel. In addition, both agents have
shown to be superior to clopidogrel in preventing recurrent ischemic events in the setting of
acute coronary syndromes (ACS). Understanding how to switch patients from prasugrel to
ticagrelor is an unmet need of clinical interest. The proposed PD investigation will have a
prospective, randomized, parallel design aimed to show that switching patients from prasugrel
to ticagrelor provides similar levels of platelet inhibition.